DESVENLAFAXINE SUCCINATE - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for desvenlafaxine succinate and what is the scope of freedom to operate?
Desvenlafaxine succinate
is the generic ingredient in two branded drugs marketed by Actavis Labs Fl, Alembic, Hikma, Intellipharmaceutics, Lupin Ltd, Norvium Bioscience, Rubicon, Yichang Humanwell, Zydus Pharms, and Pf Prism Cv, and is included in eleven NDAs. There is one patent protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Desvenlafaxine succinate has twenty-two patent family members in sixteen countries.
There are eleven drug master file entries for desvenlafaxine succinate. Twenty-two suppliers are listed for this compound.
Summary for DESVENLAFAXINE SUCCINATE
International Patents: | 22 |
US Patents: | 1 |
Tradenames: | 2 |
Applicants: | 10 |
NDAs: | 11 |
Drug Master File Entries: | 11 |
Finished Product Suppliers / Packagers: | 22 |
Raw Ingredient (Bulk) Api Vendors: | 44 |
Clinical Trials: | 40 |
Patent Applications: | 537 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for DESVENLAFAXINE SUCCINATE |
What excipients (inactive ingredients) are in DESVENLAFAXINE SUCCINATE? | DESVENLAFAXINE SUCCINATE excipients list |
DailyMed Link: | DESVENLAFAXINE SUCCINATE at DailyMed |
Recent Clinical Trials for DESVENLAFAXINE SUCCINATE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Phase 3 |
Seoul National University Bundang Hospital | Phase 4 |
Korea Cancer Center Hospital | Phase 4 |
Pharmacology for DESVENLAFAXINE SUCCINATE
Drug Class | Serotonin and Norepinephrine Reuptake Inhibitor |
Mechanism of Action | Cytochrome P450 2D6 Inhibitors Norepinephrine Uptake Inhibitors Serotonin Uptake Inhibitors |
Medical Subject Heading (MeSH) Categories for DESVENLAFAXINE SUCCINATE
Anatomical Therapeutic Chemical (ATC) Classes for DESVENLAFAXINE SUCCINATE
Paragraph IV (Patent) Challenges for DESVENLAFAXINE SUCCINATE
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
PRISTIQ | Extended-release Tablets | desvenlafaxine succinate | 25 mg | 021992 | 1 | 2015-05-08 |
PRISTIQ | Extended-release Tablets | desvenlafaxine succinate | 50 mg and 100 mg | 021992 | 12 | 2012-02-29 |
US Patents and Regulatory Information for DESVENLAFAXINE SUCCINATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Zydus Pharms | DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 204020-001 | Oct 11, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Lupin Ltd | DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 204172-001 | Jun 29, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Lupin Ltd | DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 204172-002 | Jun 29, 2015 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Hikma | DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 204082-002 | Aug 28, 2017 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Rubicon | DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 204028-003 | Dec 7, 2023 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Actavis Labs Fl | DESVENLAFAXINE SUCCINATE | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 204065-001 | Jul 29, 2016 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DESVENLAFAXINE SUCCINATE
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-002 | Feb 29, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-003 | Aug 20, 2014 | ⤷ Sign Up | ⤷ Sign Up |
Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-002 | Feb 29, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-001 | Feb 29, 2008 | ⤷ Sign Up | ⤷ Sign Up |
Pf Prism Cv | PRISTIQ | desvenlafaxine succinate | TABLET, EXTENDED RELEASE;ORAL | 021992-001 | Feb 29, 2008 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DESVENLAFAXINE SUCCINATE
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Poland | 350924 | ⤷ Sign Up | |
European Patent Office | 1905757 | ⤷ Sign Up | |
Cyprus | 1108202 | ⤷ Sign Up | |
Hungary | 0200898 | ⤷ Sign Up | |
Austria | 397581 | ⤷ Sign Up | |
European Patent Office | 2133325 | ⤷ Sign Up | |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.